Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China’s FDA accepts to review CASI’s MARQIBO
CASI’s China rights to MARQIBO was licensed from its partner Spectrum Pharmaceuticals, Inc. MARQIBO is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S.
CASI’s China rights to MARQIBO was licensed from its partner Spectrum Pharmaceuticals, Inc. MARQIBO is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S.
This milestone was reached in 2015 which will be recognised in the financial year 2015. The agreement between Evotec and Janssen for this collaboration became effective on October
The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA). Ionis Pharmaceuticals COO Lynne Parshall said: "Achieving our target enrollment number
The clinical trial is expected to begin in the first half of 2016. PLX-R18 is Pluristem’s second cell therapy product cleared for clinical studies by the U.S. FDA.
A MAP will allow Cytori, upon completion of the statutory legal and regulatory requirements, to offer patients and their healthcare providers access to Cytori Cell TherapyTM, known as
The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. These programs will be
Under terms of the agreement, Merck, through a subsidiary, will acquire IOmet, including its comprehensive pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors. Based
Under terms of the agreement, AMRI will develop and initially provide cGMP manufacturing and analytical support for the registration of the new product candidates. Eagle will be responsible
Under the agreement, Sorrento will sponsor preclinical and clinical research & development programs focused on NK biology as well as adoptive NK cell therapies and, in return, obtain
"This study is designed to use a risk-based approach to treat younger patients with AML," said Professor Nigel Russell, Centre for Clinical Haematology, Nottingham University Hospital, the trial’s